Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET)
CUSIP: 007002108
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.0001
- Shares outstanding
- 9,599,852
- Total 13F shares
- 63,950,445
- Share change
- -11,212,870
- Total reported value
- $77,407,916
- Put/Call ratio
- 844%
- Price per share
- $1.21
- Number of holders
- 83
- Value change
- -$23,984,627
- Number of buys
- 44
- Number of sells
- 55
Quarterly Holders Quick Answers
What is CUSIP 007002108?
CUSIP 007002108 identifies ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 007002108:
Top shareholders of ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
119%
|
11,447,140
|
$26,900,779 | — | 31 Mar 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
79%
|
7,541,000
|
$17,721,350 | — | 31 Mar 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
67%
|
6,407,400
|
$15,057,390 | — | 31 Mar 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
64%
|
6,181,671
|
$14,526,927 | — | 31 Mar 2024 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
43%
|
4,134,631
|
$9,716,383 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
43%
|
4,106,170
|
$9,649,500 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
42%
|
4,067,305
|
$9,558,166 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
42%
|
4,005,587
|
$9,413,130 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
35%
|
3,373,232
|
$7,927,097 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
33%
|
3,126,578
|
$7,347,458 | — | 31 Mar 2024 | |
| Carlyle Group Inc. |
13F
|
Company |
31%
|
2,948,718
|
$6,900,000 | — | 31 Mar 2024 | |
| Commodore Capital LP |
13F
|
Company |
14%
|
1,374,320
|
$3,229,652 | — | 31 Mar 2024 | |
| Blackstone Inc. |
13F
|
Company |
13%
|
1,236,453
|
$2,905,665 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
13%
|
1,204,961
|
$2,831,855 | — | 31 Mar 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
12%
|
1,134,400
|
$2,665,840 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
11%
|
1,049,000
|
$2,465,000 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
9.8%
|
940,234
|
$2,209,550 | — | 31 Mar 2024 | |
| COWEN AND COMPANY, LLC |
13F
|
Company |
9%
|
860,143
|
$2,021,336 | — | 31 Mar 2024 | |
| Octagon Capital Advisors LP |
13F
|
Company |
8%
|
767,799
|
$1,804,328 | — | 31 Mar 2024 | |
| Woodline Partners LP |
13F
|
Company |
7.7%
|
735,095
|
$1,727,473 | — | 31 Mar 2024 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
6.8%
|
655,665
|
$1,540,813 | — | 31 Mar 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
6.3%
|
600,000
|
$1,410,000 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
5.4%
|
521,571
|
$1,225,692 | — | 31 Mar 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
5.3%
|
506,039
|
$1,189,192 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
4.5%
|
435,615
|
$1,023,696 | — | 31 Mar 2024 | |
| NORGES BANK |
13F
|
Company |
4.5%
|
429,550
|
$1,009,443 | — | 31 Mar 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
4.3%
|
416,294
|
$978,291 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
4.3%
|
410,636
|
$964,994 | — | 31 Mar 2024 | |
| JOHNSON & JOHNSON |
13F
|
Company |
3.8%
|
364,472
|
$856,509 | — | 31 Mar 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
3.7%
|
355,343
|
$834,000 | — | 31 Mar 2024 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.5%
|
331,279
|
$778,506 | — | 31 Mar 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
3.4%
|
325,949
|
$765,980 | — | 31 Mar 2024 | |
| Atom Investors LP |
13F
|
Company |
2.7%
|
259,307
|
$609,371 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.5%
|
238,214
|
$559,803 | — | 31 Mar 2024 | |
| XTX Topco Ltd |
13F
|
Company |
2.4%
|
226,049
|
$531,215 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
2%
|
194,201
|
$456,372 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
2%
|
189,327
|
$444,919 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
1.6%
|
150,076
|
$352,679 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
1.5%
|
146,052
|
$343,221 | — | 31 Mar 2024 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
1.5%
|
141,548
|
$332,638 | — | 31 Mar 2024 | |
| EXCHANGE TRADED CONCEPTS, LLC |
13F
|
Company |
1.4%
|
138,993
|
$326,634 | — | 31 Mar 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
129,800
|
$305,030 | — | 31 Mar 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
1.1%
|
109,241
|
$256,716 | — | 31 Mar 2024 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
1.1%
|
107,200
|
$251,920 | — | 31 Mar 2024 | |
| Francesco Galimi |
3/4/5
|
SVP & Chief Medical Officer |
—
mixed-class rows
|
476,878
mixed-class rows
|
$244,322 | — | 05 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.1%
|
101,999
|
$239,697 | — | 31 Mar 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.64%
|
61,891
|
$145,444 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.63%
|
60,496
|
$142,157 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.62%
|
59,243
|
$139,221 | — | 31 Mar 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.61%
|
58,590
|
$137,686 | — | 31 Mar 2024 |
Institutional Holders of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) as of Q2 2024
As of 30 Jun 2024,
Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) was held by
83 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
63,950,445 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, TANG CAPITAL MANAGEMENT LLC, RA CAPITAL MANAGEMENT, L.P., GOLDMAN SACHS GROUP INC, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, Carlyle Group Inc., Aquilo Capital Management, LLC, RENAISSANCE TECHNOLOGIES LLC, and Blackstone Inc..
This page lists
84
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
96
Q2 2024 holders
83
Holder diff
-13
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.